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INTRODUCTION
Clobazam is a benzodiazepine, but it is the only 1,5-benzodiazepine available on the market since all other benzodiazepines have a 1,4 structure. Its nitrogen atoms occupy the 1 and 5 position, a keto group is placed in the 4 position, and the remainder of the molecule is analogous to diazepam. 1 Benzodiazepines act mainly by binding to γ-aminobutyric acid (GABA)-A receptors and increasing their affinity to GABA, and are considered GABA-A allosteric modulators. 2 This action probably explains their antiepileptic properties. 3 Clobazam was first approved in Australia in 1970 and then in France in 1974 for anxiety and epilepsy. 4 Clobazam demonstrated clinical benefit in more than 50 European epilepsy studies which reported data on >3000 pediatric and adult patients, 300 of whom were diagnosed with Lennox-Gastaut syndrome. 1 This led to 2 multicenter randomized clinical trials (RCTs) 5, 6 for Lennox-Gastaut syndrome using a double-blind design, and to the subsequent marketing in the US in October of 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.
Bentué-Ferrer et al. 
METHODS
Articles for this review were obtained from a PubMed search completed in January 2012 and then updated in April 2012. The search had no time limit and used the word "clobazam". The first author reviewed all abstracts and selected all relevant articles to be read. Moreover, all article bibliographies were carefully reviewed for additional important articles not found in the PubMed search. The first author completed this computer search in the context of developing a practical guideline for the use of clobazam in epilepsy as he has done with all antiepileptic drugs marketed in the US. 14 Thus, the original computer search included all available clobazam articles, not only those focused on TDM or pharmacokinetics.
More than two hundred clobazam articles were carefully reviewed. Only those relevant to TDM are included in this review article.
Clobazam pharmacokinetics is characterized by two peculiarities: 1) it has an active metabolite;
and 2) it is mainly metabolized by two cytochrome P450 (CYP) isoenzymes, CYP3A4 and the polymorphic CYP2C19.
A drug plasma concentration-to-dose (C/D) ratio is calculated by dividing the drug trough steady-state concentration by the dose that the patient is taking. In the opinion of the authors, the C/D ratio may be extraordinarily helpful in moving TDM forward, but this concept has suffered from too little representation in the literature. There are no comprehensive reviews of the application of this concept to TDM. According to a PubMed search, it was first used in a published research article in 1975. 15 The C/D ratio has frequently been used by researchers working in TDM. Unfortunately, although their research has been published in journals like this one, or others with an interest in TDM and/or pharmacokinetics, the C/D ratio concept is not usually described in pharmacological textbooks 16 or in comprehensive textbooks focused on pharmacokinetics. 17 The C/D ratio, which can be considered a proxy of drug clearance, is at the core of a new family of pharmacokinetic mathematical models whose empirical and theoretical adequacy has been demonstrated in a number of studies. 18, 19 Although there is no room in this article to describe these models, which are essentially statistical random-effects linear models of steady-state drug concentrations, computer simulations and statistical theory have shown that clinical procedures for drug dosage individualization designed with these models may outperform some traditional procedures used in TDM. 18 The C/D ratio is inversely related to drug clearance; thus, a high C/D ratio indicates poor drug clearance and a low C/D ratio indicates rapid clearance. In addition, basic compartmental theory predicts that, for a fixed dose, the C/D ratio obtained from TDM studies is directly proportional to the area under the curve (AUC0-∞), the typical measure of drug exposure used in single-dose pharmacokinetic studies.
Although empirical data are needed to better study this relationship, a high AUC should be associated with a high C/D ratio and a low AUC should be associated with a low C/D ratio, bearing in mind that comparing C/D ratios and AUCs requires comparable doses.
LITERATURE REVIEW
The information was classified into five major topics: clobazam metabolism, clobazam versus Ndesmethylclobazam activity, clobazam and N-desmethylclobazam half-lives (Table 1) , TDM issues (Table 2) , and the use of serum concentration ratios to interpret clobazam pharmacokinetics in TDM.
Four serum concentration ratios are used to interpret clobazam metabolism: the Ndesmethylclobazam/clobazam ratio (Table 3) , which is the most established ratio in the literature, and three C/D ratios: clobazam C/D ratio (Table 4) , N-desmethylclobazam C/D ratio (Table 5) , and the total clobazam C/D ratio ( Table 6 ). The total clobazam C/D ratio is calculated by dividing the sum of plasma clobazam and N-desmethylclobazam concentrations by the dose. These four sections reviewing serum ratios on steady state TDM studies are supplemented with the review of the analogous AUC ratios in single-dose studies (Table 7) .
7
CYP3A4. CYP3A4 is responsible for most CYP3A-mediated drug metabolism but the minor isoforms CYP3A5, CYP3A7 and CYP3A43 also can contribute. 24 Since there is no data indicating that the minor isoforms are relevant for clobazam metabolism, this section focuses only on CYP3A4. CYP3A4 is the most important CYP enzyme in the liver and gut; and there is limited understanding of how its different genetic variations contribute to its function. However, there is definitive agreement that there are no CYP3A4 PMs. 25, 26 There is also definitive agreement that environmental factors such as inducers and inhibitors have major effects on CYP3A4 function. Some antiepileptic drugs (carbamazepine, phenobarbital and phenytoin) and rifampin are major CYP3A4 inducers. 13, 27 Erythromycin (and some related compounds), ketoconazole (and some related compounds) and nefazadone are major CYP3A4 inhibitors. 13 ,27 A potential confounder in CYP3A4 studies is that CYP3A4 shares substrates, inhibitors and inducers with p-glycoprotein, making it difficult to distinguish the metabolic contributions of CYP3A4 and pglycoprotein for a particular drug.
There is also information that personal characteristics such age, gender and pregnancy may influence CYP3A4 activity. Neonates and infants have lower CYP3A4 activity but children from 1 to 12 years of age have greater CYP3A4 activity than adults. 28 Geriatric age does not appear to decrease CYP3A4 activity. 29 On average, females may have 20-50% higher activity than males 30 but this may be explained by differences in p-glycoprotein rather in CYP3A4 activity. 31 Pregnant women may have increased CYP3A4 activity.
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Clobazam auto-induction. In vivo controlled studies indicate that clobazam increases the metabolism of the CYP3A4 substrate midazolam, since it: (1) decreases midazolam AUC by 27%, and (2) increases the AUC of the metabolite 1-hydroxymidazolam by 4-fold. 33 The prescribing information provides conflicting information on the clinical relevance of the CYP3A4 induction by clobazam since it states that "this level of induction does not call for dosage adjustment of drugs that are primarily metabolized by CYP3A4", but then states that the addition of clobazam may be associated with the loss of contraceptive efficacy, and non-hormonal forms of contraception are recommended when using clobazam. 20 If clobazam is both a mild CYP3A4 inducer and is metabolized by CYP3A4, then one can predict some auto-induction in patients not taking powerful CYP3A4 inducers. This happened in one study in healthy volunteers 34 (see subsection on auto-induction in the section on clobazam C/D ratio).
CYP2C19.The CYP2C19 gene encodes for S-mephenytoin hydroxylase. The most frequent allele is CYP2C19*1, which has normal enzyme activity. 35 The two most common allelic variants are CYP2C19*2 and CYP2C19*3, which result in a nonfunctional enzyme. The CYP2C19*2 allele is particularly frequent in East Asians; approximately 10%-25% of Asians are classified as CYP2C19 PMs with two nonfunctional alleles, while fewer than 5% of people from other ethnic backgrounds are classified as CYP2C19 PMs. 35 In a large US study, 36 CYP2C19 PM prevalence was 2.2% in Caucasians (95% confidence interval, CI, 1.6%-2.5%) and 4.0% in African Americans (CI 2.6%-6.1%). Being an East Asian with poor tolerance to usual diazepam doses may reflect a CYP2C19 PM genotype. 37,38 A new CYP2C19 *17 allele has been described and may be associated with the ultrarapid metabolizer phenotype for CYP2C19 drugs. 39 In 146 Swedes, the prevalence of homozygous subjects (*17/*17) was 2.7%.
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There are no published studies of the effects of this new CYP2C19 allele in clobazam metabolism.
According to the prescribing information, N-desmethylclobazam AUC was approximately 3-5 times higher in CYP2C19 PMs and 2 times higher in subjects with only 1 active allele than in subjects with 2 active alleles. 20 The prescribing information makes two statements that may be somewhat contradictory: (1) systemic exposure of clobazam is similar for both CYP2C19 PMs and non-PMs, and (2) clobazam dosage in known CYP2C19 PMs may need to be adjusted. Their practical recommendation is that in adult patients known to be CYP2C19 PMs, the starting dose should be 5 mg/day instead of 10 mg/day, and dose titration should proceed slowly up to 20 mg/day and be based upon clinical response.
An additional titration to the maximum dose of 40 mg/day may be started on day 21. 20 There is limited independent information on how CYP2C19 polymorphism influences clobazam antiepileptic response. Seo et al. 40 published a retrospective Japanese study including 25 PMs, 44 subjects with only 1 active allele, and 41 subjects with 2 active alleles. The respective response rates (defined as seizure reduction ≥50%) were 65%, 47% and 33%. The odds ratio (OR) of response comparing PMs versus subjects with 1 active allele was 10.0 (95% CI, 2.5-39.6) and when comparing those with 1 active allele versus those with 2 active alleles it was 2.5 (0.88-7.3). Adverse drug reactions (ADRs) were increased in PMs, who had 64% versus 43% in those with 1 active allele and 39% in those with 2 active alleles, although these differences were borderline significant (p=0.07). This is consistent with clobazam's description as a drug with wide therapeutic range. 10 Therefore, higher levels of N-desmethylclobazam in CYP2C19 PMs may be associated with a better chance of response but some risk of increased ADRs. On the other hand, there are two published cases 41,42 of severe signs of clobazam intoxication in CYP2C19
PMs (see Table 2 ). In these 2 patients, N-desmethylclobazam had extraordinarily long-half lives. One of them still had serum N-desmethylclobazam concentrations in the therapeutic range 20 days after clobazam discontinuation, 42 and the other required complete clobazam discontinuation for 10 days to reduce serum concentrations by one-third. 41 Both cases appear to have been treated with dosages in the usual recommended ranges, but they were too high for these specific patients, which may have led to saturation of N-desmethylclobazam metabolism. 
Clobazam versus N-desmethylclobazam activity
There is definitive agreement that N-desmethylclobazam has antiepileptic activity. 46 What is not clear is how much of the clinical activity of clobazam is due to the presence of the metabolite in the body. The prescribing information 20 reported that the relative potency of N-desmethylclobazam compared to the parent compound ranges from 1/5 to equal potency. This estimation was based on animal and in vitro receptor binding data but no studies were provided as reference.
To determine the clinical relevance of N-desmethylclobazam one needs to know the differences between clobazam and N-desmethylclobazam in: (1) pharmacodynamic activity, (2) brain entrance and properties, which determine passive diffusion and/or actions of transporters such as the pglycoprotein. 51 Particularly in the benzodiazepines, brain uptake may be more closely related to lipophilicity. 52 According to prescribing information, clobazam and N-desmethylclobazam are pglycoprotein substrates 20 but data on their affinity is not provided. P-glycoprotein affinity for clobazam and its metabolite may be important, since p-glycoprotein affinities explain differences in other psychiatric drugs. A relevant drug is risperidone, in which the high affinity of p-glycoprotein for the main risperidone active metabolite may explain why the metabolite has lower ability than risperidone to penetrate the brain and lower activity level. 53 Laux et al. 54 57 , proposed that N-desmethylclobazam may be less prone to cause tolerance. To avoid the contamination of human pharmacodynamic studies by a difference in tolerance between clobazam and N-desmethylclobazam, these studies should be completed when the maximum tolerance has been acquired.
Once the relative pharmacodynamic activity under conditions of maximal tolerance and brain entrance of clobazam and N-desmethylclobazam are better established, an attempt can be made to calculate weighted serum concentrations to better predict clinical response. 58 For example, let us assume that clobazam has 3 times as much ability to penetrate the blood-brain barrier and is 2 times more potent in pharmacodynamic activity. This means that clobazam will be 6 times more potent at brain GABA-A receptors (3 times due to greater brain entrance, multiplied by 2 times due to its pharmacodynamic activity at the receptors). Therefore, weighted total clobazam serum concentrations should be calculated 
Clobazam and N-desmethylclobazam half-lives
According to the prescribing information, the estimated mean elimination half-lives of clobazam and N-desmethylclobazam were 36-42 hours and 71-82 hours, respectively. 20 No details were given on how these estimations were obtained. Recent half-life estimations from single and repeated dose studies, 33 required for marketing clobazam in the US, are described in the upper panel of Table 1 .
Nine prior studies 34,59-67 estimated half-lives in healthy volunteers after single doses of clobazam.
All 9 studies provided half-lives in non-elderly adults lower than the lowest limit (36 hours) described by the package insert, which probably reflects the difficulties of using single-dose studies to estimate halflives, and that different methods of calculating half-lives may provide different results. These studies did not report subject races. However, all studies were probably done with Caucasians since all were done in the US or European countries. In Caucasians, one should expect a low prevalence (around 2%) of CYP2C19 PMs. The recent pharmacokinetic studies by the manufacturer 33 excluded CYP2C19 PMs. The 9 prior studies included a total of 82 individuals, which may incorporate 1 or 2 CYP2C19 PMs. Only 1 study 62 included an individual with a very long N-desmethylclobazam half-life, 131 hours, which is consistent with a CYP2C19 PM profile.
One study 34 provided data from both healthy controls and patients ( half-lives to reach steady state. As a matter of fact, the graphic representation of clobazam TDM in two studies suggested that it may take up to 7 half-lives to reach a plateau. The two studies included one by Rupp et al. 64, 65 who gave 20 mg/day (10 mg twice daily) of clobazam for 28 days to 10 Indian subjects and one by Ochs et al. 61 who gave 10-mg/day clobazam doses for 22 days (5 mg twice a day) to 13 healthy volunteers. In the first study, 64, 65 it was obvious that clobazam reached a steady state within 1 week in the average patient, but reaching N-desmethylclobazam steady-state took more than 3 weeks. days) in a repeated-dose study, then the patient requires more than 1 month to reach steady-state.
In a single-dose study, Greenblatt et al. 59 demonstrated differences in clobazam half-lives between elderly and young male adults. They 70 completed a repeated-dose study of the same patients which supported the concept that elderly males have higher clobazam and desmethylclobazam half-lives ( Dosing. In spite of the relatively long clobazam and N-desmethylclobazam half-lives, the prescribing information for epilepsy recommends dosing clobazam twice a day. 20 The literature does not explain why twice a day may be needed since a clobazam half-life of 36 hours would allow for once-a-day dosing.
In their review of anxiety RCTs, Brogden et al. 79 recommended dosing clobazam 2 or 3 times a day for anxiety. They also described a preliminary study indicating that greater decreases in anxiety corresponded to clobazam peak values. Thus, it possible that administering clobazam twice a day, which provides 2 peaks, will determine potentially greater anti-anxiety effects which occur in the peaks.
TDM issues
Therapeutic window. Steady-state serum clobazam and N-desmethylclobazam concentrations are described as linearly related to dose. 9, 20 There are no studies of kinetic linearity in CYP2C19 PMs.
There is limited information regarding the clobazam therapeutic concentration window or range for controlling seizures. A large naturalistic study in children 80 provided evidence that clobazam has a wide therapeutic window. In a comprehensive review, Patsalos et al. 9 stated that (1) because tolerance tends to develop to ADRs and sometimes to the therapeutic effects of clobazam, there is no clear relationship between efficacy and serum concentrations of either clobazam or N-desmethylclobazam; and (2) therapeutic clobazam doses were associated with serum concentrations of 30-300 ng/mL for the parent drug and 300-3000 ng/mL for N-desmethylclobazam. In another review, Neels et al. 81 recommended a clobazam therapeutic range of 100-400 ng/mL, but provided no range for Ndesmethylclobazam. In a sample of 11 consecutive patients (including many with DDIs), Contin et al. 22 described median serum concentrations of 200 ng/mL (range, 80-560) for clobazam and 1370 ng/mL (range, 200-5000) for N-desmethylclobazam. In 39 adults, Guberman et al. 82 reported that all 6 patients who had ADRs that appeared to be dose-related had plasma concentrations >900 ng/mL for Ndesmethylclobazam. Tables 3 to 6 provides data on these 4 ratios extracted from published TDM studies. The footnote b of Table 4 provides a clarification regarding units for C/D ratios. Table 7 reviews additional information obtained from studies computing AUCs that complements TDM studies (see footnote a for details).
N-desmethylclobazam/clobazam ratio
As clobazam is mainly metabolized by CYP3A4, and N-desmethylclobazam by CYP2C19, the Ndesmethylclobazam/clobazam ratio is influenced by the activity of both CYP enzymes. Therefore, a high N-desmethylclobazam/clobazam ratio can indicate: (1) the presence of a CYP2C19 PM or the coprescription of a potent CYP2C19 inhibitor, (2) the co-prescription of a CYP3A4 inducer, or (3) both. indicate that the patient is a CYP2C19 PM, or is taking a drug which is a CYP3A inducer and a CYP2C19
inhibitor, such as felbamate; (2) 
Clobazam C/D ratio
The clobazam C/D ratio may be mainly a measure of CYP3A4 activity. Table 4 presents a comprehensive review of the few published studies that provided data either peak or trough concentrations (see footnote a) that can be used to calculate clobazam C/D ratio. 22, 41, 48, 61, 69, [88] [89] [90] [91] If the clobazam C/D ratio is a measure of CYP3A4 activity the following predictions can be made, it should: 1) be lower in patients taking inducers than in normal controls; 2) change with time if
clobazam auto-induces its metabolism; 3) be lower in children 1-12 years than in adults; 4) be higher in patients taking CYP3A4 inhibitors; and 5) not be influenced by CYP2C19 inhibitors.
Inducers. Table 4 indicates that normal subjects appear to have clobazam C/D <30 while patient takings inducers show clobazam C/D ratios <10, which is consistent with greater CYP3A4 activity.
The average clobazam concentration decreased by 62% (from 354 to 136 ng/mL) 91 in the only well-controlled study of induction. This study used subtherapeutic doses of carbamazepine (400 mg/day) and a too short (2 weeks) duration to reach maximal induction. Naturalistic studies indicate: 1) patients taking phenytoin or carbamazepine had significantly lower C/D ratios corrected by weight; 34 2) trough weight-corrected clobazam C/D ratio appeared to be 10 times higher in the volunteers than in adult patients presumably taking inducers; 34 and 3) no significant differences in clobazam peak concentrations were observed before and after carbamazepine administration, but N-desmethylclobazam concentration increased significantly. 34 In a single-dose study 92 measuring AUCs, clobazam clearance was increased by carbamazepine and phenytoin (Table 7) .
Auto-induction. Bun et al. 34 ,88 compared peak and trough weight-corrected clobazam C/D ratios from 6 healthy volunteers and 17 patients (6-32 years) with co-medications. In patients who were presumably taking inducers, there was a very small increase from day 2 to day 21. It is interesting that in healthy volunteers both peak and trough weight-corrected clobazam C/D ratios increased from day 2 to day 7, and then decreased to day 21. In healthy volunteers at day 7, when steady state has not been reached, one would expect that all C/D ratios, clobazam C/D, N-desmethylclobazam C/D and total C/D ratios, should be lower than those at day 28. However, it is striking that 5 of 6 patients had clobazam C/D ratios that were 20-30% higher at day 7 than at day 28. This is consistent with self-induction, which is manifested by decreased clobazam concentrations at day 28 compared to day 7.
In a pharmacokinetic study using 10 mg/day of clobazam for 22 days, focused on 12 young and 12 elderly adults, no signs of self-induction in clobazam metabolism were observed. 
N-desmethylclobazam C/D ratio
Bun et al. 34 found that peak weight-corrected N-desmethylclobazam C/D ratios were very mildly elevated when compared with trough weight-corrected N-desmethylclobazam C/D ratios. This is compatible with the findings that 1) N-desmethylclobazam has a very long half-life and 2) there are small differences between studies using peaks or trough N-desmethylclobazam measures. Table 5 The N-desmethylclobazam C/D ratio has been described by some studies. However, it is not a good measure because it is influenced by both CYP3A4 and CYP2C19 activity and may not solely reflect clobazam clearance. There is no consistent pattern for the N-desmethylclobazam C/D ratio in Table 5 .
Other studies indicate how inducers, age, CYP3A4 inhibitors, CYP2C19 inhibitors and CYP2C19 PM phenotype may influence N-desmethylclobazam C/D ratio.
Inducers. In 414 patients from 9 months to 40 years of age, Bun et al. 34 measured peak concentrations three hours after clobazam morning dose and calculated an N-desmethylclobazam C/D ratio corrected for weight. They found that those taking phenytoin or carbamazepine had significantly higher values. In a subsample of 10 patients, there were significant differences in N-desmethylclobazam peak concentrations before (727 ng/mL) and after (1720 ng/mL) carbamazepine administration (the concentration more than doubled). Another study in the same article focused on the comparison of 6 healthy volunteers with 17 patients (6 -32 years) with co-medications. The trough weight-corrected N-desmethylclobazam C/D ratio appeared to be more than twice as high in healthy volunteers as in adult patients. The co-medications were not described.
Contin et al. 89 found that felbamate was associated with 5 times higher weight-adjusted Ndesmethylclobazam C/D ratios. Jawad et al. 92 compared 6 adult controls with 6 adult epileptic patients who took a single dose of clobazam on stable phenytoin or carbamazepine doses for 3 months. Ndesmethylclobazam AUC increased by a factor of 5.24 on phenytoin versus a factor of 1.66 on carbamazepine (Table 7) . In a study administering N-desmethylclobazam 30 mg/day for 2 weeks, Pullar et al. 63 compared 8 healthy controls, 5 female patients and 3 male patients. The male controls had median N-desmethylclobazam C/D ratios of 40.5 (ng × mg)/(mL × day) (range 36.7-55). The 5 female patients had slightly elevated ratios with a median of 63.3 (ng × mg)/(mL × day) (range 40.3-76.7). All 3 male patients were taking phenytoin and had ratios twice as high, with a median of 82.3 (ng × mg)/(mL × day) (range 77.6-95.0).
Age. Bun et al. 34 provided graphic results for trough weight-corrected N-desmethylclobazam C/D ratios, which appeared to be roughly twice as high in adult as in child patients. Co-medication was not described and the study included only 17 patients. In a larger sample of 414 patients, trough weight-corrected Ndesmethylclobazam C/D ratios were significantly lower in children than in adults.
CYP3A4 and CYP2C19 inhibitors.
There are no steady-state TDM studies on the effects of CYP3A4 or CYP2C19 inhibitors on the N-desmethylclobazam C/D ratio. Table 7 describes a single-dose study 33 by clobazam maker using ketoconazole (CYP3A4 inhibitor) and omeprazole (CYP2C19 inhibitor). This limited data indicated that there were almost no increases in the N-desmethylclobazam AUC on ketoconazole (12% or multiplied by a factor of 1.12), but there was an important increase on omeprazole (65% or multiplied by a factor of 1.65). Under steady state conditions for omeprazole and clobazam these effects may be larger. Table 4 Table 6 presents a comprehensive review of the few published studies that provided data pertaining to total C/D ratios. 22, 41, 61, 69, 88, 91 Although little can be concluded from this limited information, most normal subjects appear to have total C/D ratios < 100. CYP2C19 PMs appear to have total C/D ratios >200.
CYP2C19 PMs.

Total C/D ratio
CYP3A4 and CYP2C19 inhibitors.
There are no steady-state TDM studies on the effects of CYP3A4 or CYP2C19 inhibitors on the total C/D ratio. carbamazepine was associated with a very small increase in total AUC (Table 7) .
In summary, no prior study has calculated total C/D ratios. The limited data on total C/D ratios and total AUCs suggest that the total C/D ratio may have reasonable potential for being a good measure 
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Clobazam versus N-desmethylclobazam activity
Better studies on the relative potency of N-desmethylclobazam compared to the parent compound are needed. 95 This is a major requirement to make clobazam TDM a better instrument in the prediction of response and ADRs. Unfortunately, it is not easy to study this issue in a definitive way. In vivo human studies combining TDM and brain imaging of GABA receptors after maximal tolerance has been acquired may be needed to definitively explore this issue. Studies combining TDM and brain imaging may provide information on the GABA-A binding activity of clobazam and N-desmethylclobazam which would allow the establishment of weighted total serum concentrations 58 for the average individual and initial exploration of interindividual variability. Considerable research studies or even new research approaches will be required to personalize clobazam pharmacokinetics and pharmacodynamics according to the genetic, environmental and personal characteristics of each individual.
CYP2C19 PM
CYP2C19 PMs may require much higher periods to reach a steady state than normal individuals.
They may take several months to reach this state. Therefore, dose increases in these subjects should be extraordinarily slow. The limited data available from a few intoxicated patients suggest that it is possible that CYP2C19 saturation may occur in these subjects when high but therapeutic doses are prescribed.
Clobazam TDM may be crucial in identifying these subjects. In the absence of CYP2C19 inhibitors, an N-desmethylclobazam/clobazam ratio >25 may be suggestive of a CYP2C19 PM genotype.
Therapeutic window
The lack of good prospective studies limits our information on clobazam therapeutic range. The lack of publication of TDM data from recent RCT trials 5, 6 on Lennox-Gastaut is a major limitation.
Tolerance to efficacy and ADRs may also decrease the value of TDM. There is no definitive agreement on the relevance of tolerance for clobazam response. Older reviews provide estimations of tolerance development ranging from 1/3 78 to 89%. 96 Some recent reviews comment that the problem of tolerance may have been overestimated. 97, 98 Currently, the best approximation to a therapeutic window or range is that of Patsalos et al. 9 They described therapeutic clobazam doses as those associated with serum concentrations of 30-300 ng/mL for the parent drug and 300-3000 ng/mL for N-desmethylclobazam. If a patient on TDM has concentrations within these ranges and has not responded, then the patient is not likely to respond to clobazam treatment.
Clobazam probably has a wide therapeutic window, making only very high concentrations relevant to help diagnose toxicity. If there are symptoms consistent with clobazam intoxication, the presence of very high concentrations (>3000 ng/mL for clobazam and/or >12,000 ng/mL for Ndesmethylclobazam) probably confirm clobazam intoxication.
N-desmethylclobazam/clobazam ratio
The available limited data suggest that the N-desmethylclobazam/clobazam ratio can be useful for
clinicians. This review suggests that: (1) very high ratios (>25) indicate that the patient is a CYP2C19
PM or taking a CYP3A4 inducer and CYP2C19 inhibitor such as felbamate; (2) Future clobazam TDM studies need to examine the effects of topiramate and oxcarbazepine on the N-desmethylclobazam/clobazam ratio. These two drugs are both weak CYP2C19 inhibitors and weak CYP3A4 inducers. Unfortunately, the actions of these drugs are not easy to study since the dosing level may be significant. It is believed 44 that only high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 mg/day) may cause CYP3A4 induction. In low and average doses, only their CYP2C19 inhibitory properties may be evident.
Total C/D ratio
The previously published literature does not describe the total C/D ratio. Future studies should explore whether it is a good measure to distinguish individuals according to their drug clearance ability.
From the available knowledge on pharmacological mechanisms, using this ratio may be more reasonable than using the N-desmethylclobazam C/D ratio. It is possible that renal impairment associated with aging, particularly in males, 70 may be associated with high total C/D ratios.
Clobazam C/D ratio
The The patient sample included 17 patients (numbers of children and adults were not specified).
n The same subjects who took part in the single-dose study.
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o These are wash-out half-lives. Overdose case i Death a A 4-year-old male developed intoxication signs after adding 15 mg/day (0.75b mg/kg/day) of clobazam to lamotrigine. The patient had repeated serum concentration measures and was interpreted as an Ndesmethylclobazam poor metabolizer (PM). Clobazam was discontinued for 10 days and restarted with a dose of 7.5 mg/day. b In a US epilepsy center 251 patients were treated with clobazam. One of them was described as suffering from clobazam intoxication; no data is provided on dose or co-medications. c The conversion of μmol/L to ng/mL (for clobazam 1.0 μmol/L=333 ng/mL and for Ndesmethlyclobazam 1.0 μmol/L=349 ng/mL) was based on Patsalos et al. d A 44-year-old male developed intoxication signs after adding an antiretroviral agent, etravirine, which is a CYP3A4 inducer and CYP2C19 inhibitor, to antiepileptic treatment of clobazam and valproate. e A 10-year-old female developed severe somnolence with increased weight and enuresis. She was initially treated with 0.6 mg/kg/day (20 mg/d) and then her dose was decreased to 0.4 mg/kg/day (12 mg/d). The patient was thought to be an N-desmethylclobazam PM, possibly a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) and possibly a rare undetected CYP2C19 inactive allele. Twenty days after discontinuation, she had N-desmethylclobazam concentrations of 6,500 ng/mL while clobazam was below the level of detection (<10 ng/mL).This patient appears also to be case report 2 in another article. Table 4 includes studies with trough and peak concentrations. The study by Ochs et al. 61 suggested major variations (by 48%) between clobazam trough and peak concentrations. Similarly, Bun et al. 34 presented clobazam C/D ratios corrected by weight at trough and peak (3 hours after clobazam dose) points on the 21st day of clobazam treatment from 6 healthy volunteers and 17 patients (6-32 years old) taking comedications. The peak weight-corrected clobazam C/D ratio appeared to be roughly twice as high as the trough C/D ratio in both healthy volunteers and patients. Therefore, the use of either peak or trough concentrations in different studies may seriously contaminate comparisons of C/D ratios data in this table. b Most TDM articles use ng/mL to measure clobazam levels. When using ng/mL for concentration and mg/day for dosing, C/D ratio units are (ng × day)/(mL × mg). This is a reasonable approximation and an easy measure for clinicians. In strict pharmacological terms, it would be better to transform the clobazam concentration to μmol/L and the daily dose to μmol/day. This would make calculations more accurate but much harder for clinicians to estimate. According to Patsalos et al. 9 1.0 μmol/L is equivalent to 333 ng/mL for clobazam, and 1.0 μmol/L is equivalent to 349 ng/mL for N-desmethylclobazam. This is a minor difference of 5% (349/333=1.05) between both molar transformations on N-desmethylclobazam versus clobazam. A 5% error is made when the differences in molecular weights between Ndesmethylclobazam and clobazam are disregarded by calculating C/D ratios using ng/mL. This increases the weight of serum N-desmethylclobazam concentrations by 5% more than would be the case if molar concentrations were used. Thus avoiding the tedious (and probably confusing for clinicians) molar transformations makes a reasonable error of only 5%. When clobazam TDM studies focus only on adults, using this (ng × day)/(mL × mg) unit for C/D ratios is reasonable. When the studies include children, there is a need to correct the dose by weight using mg/kg × day, and to make the unit for C/D ratios (ng × day×kg)/(mL × mg). Tables 4-6 Ratio ranges were not provided. These are Italian children or adults. Three of 11 controls were taking inducers. Eight of the controls had 2 active CYP2C19 alleles and 3 had only 1 active allele. j Italian child who was a CYP2C19 PM. k Italian child who appeared to be a CYP2C19 PM due to the presence of a CYP2C19 inactive allele (*2) and possibly a rare undetected CYP2C19 inactive allele. This patient also appeared to be published as an individual case report in another article. p These include 9 patients on monotherapy. There were15 patients on valproate with a mean clobazam C/D ratio of 699 (ng ×kg/ml)/(mg/day) that corresponds to 9.99 (ng /ml)/(mg/day) in a hypothetical person of 70 kg, which is not included in this line of the table. q These include 17 patients on carbamazepine with a mean clobazam C/D ratio of 492 (ng ×kg/ml)/(mg/day) that corresponds to 7.0 (ng /ml)/(mg /day) in a hypothetical person of 70 kg; and 5 patients on phenytoin with a mean clobazam C/D ratio of 497 (ng ×kg/ml)/(mg/day) that corresponds to 7.1 (ng /ml)/(mg/day) in a hypothetical person of 70 kg. There were 17 patients on phenobarbital with a mean clobazam C/D ratio of 373 (ng ×kg/ml)/(mg/day) that corresponds to 5.3 (ng /ml)/(mg/day) in a hypothetical person of 70 kg, which is not included in this line of the table. 
